Reid Marion E
Director Immunohematology, New York Blood Center, 310 East 67 Street, New York, NY 10065, Telephone: 212 570 3294, ,
Transfus Med Hemother. 2009 Jun;36(3):168-178. doi: 10.1159/000212062.
DNA-based tests are increasingly being used to predict a blood group phenotype. This is possible because genes encoding 29 of the 30 blood group systems have been cloned and sequenced, and the molecular bases associated with most antigens have been determined. RBCs carrying a particular antigen, if introduced into the circulation of an individual who lacks that antigen, can elicit an immune response. It is the antibody from such an immune response that causes problems in clinical practice and the reason why antigen-negative blood is required for safe transfusion. The classical method of testing for blood group antigens and antibodies is hemagglutination; however, it has certain limitations, some of which can be overcome by testing DNA. Such testing allows conservation of antibodies for confirmation by hemagglutination of predicted antigen-negativity. High-throughput platforms provide a means to test relatively large numbers of donors, thereby opening the door to change the way antigen-negative blood is provided to patients. This chapter discusses how molecular approaches can be applied in transfusion medicine, and summarizes experiences of using laboratory developed tests and DNA arrays at the New York Blood Center.
基于DNA的检测方法越来越多地用于预测血型表型。这之所以成为可能,是因为已克隆并测序了30个血型系统中29个系统的编码基因,并且已确定了与大多数抗原相关的分子基础。携带特定抗原的红细胞,如果被引入缺乏该抗原的个体的循环系统中,可能引发免疫反应。正是这种免疫反应产生的抗体在临床实践中引发问题,也是安全输血需要抗原阴性血液的原因。检测血型抗原和抗体的经典方法是血凝反应;然而,它有一定的局限性,其中一些可以通过检测DNA来克服。这种检测可以保留抗体,以便通过对预测的抗原阴性进行血凝反应来确认。高通量平台提供了一种检测相对大量献血者血型的方法,从而为改变向患者提供抗原阴性血液的方式打开了大门。本章讨论了分子方法如何应用于输血医学,并总结了纽约血液中心使用实验室开发的检测方法和DNA阵列的经验。